Information Provided By: 
Fly News Breaks for July 23, 2018
IRWD
Jul 23, 2018 | 07:09 EDT
H.C. Wainwright analyst Raghuram Selvaraju started Ironwood Pharmaceuticals with a Sell rating and $12.50 price target. The shares are overvalued given the gradually slowing sales of Linzess, the lackluster performance of linaclotide in outside the U.S. markets, commercial disappointments with the company's gout franchise and recent clinical setbacks with itts development-stage candidates beyond Linzess, Selvaraju tells investors in a research note.
News For IRWD From the Last 2 Days
There are no results for your query IRWD
